India, Nov. 13 -- Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical, on Friday reported a wider third-quarter loss, reflecting higher general and administrative expenses.
The company posted a net loss of $38.7 million, or $2.46 per share, compared to a net loss of $35.3 million, or $2.28 per share, in the year-ago quarter.
Revenue was $2 million, compared to no revenue in the prior-year period, reflecting an upfront payment under a non-exclusive patent license agreement with Pfizer Inc.
Research and development expenses declined to $26 million from $28.5 million, while general and administrative expenses increased to $7.8 million from $5.3 million.
Total other expense rose to $7 million from $1.4 million, primarily du...